Fresenius/€FRE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Fresenius
- Ticker
- €FRE
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 179,493
- Headquarters
- Bad Homburg vor der Höhe, Germany
- Website
- www.fresenius.com
Fresenius Metrics
BasicAdvanced
€30B
19.33
€2.75
0.77
€1.05
1.98%
Price and volume
Market cap
€30B
Beta
0.77
52-week high
€54.32
52-week low
€42.10
Average daily volume
982K
Dividend rate
€1.05
Financial strength
Current ratio
1.52
Quick ratio
0.817
Long term debt to equity
0.506
Total debt to equity
0.57
Dividend payout ratio (TTM)
32.15%
Interest coverage (TTM)
5.59%
Profitability
EBITDA (TTM)
3,097.4
Gross margin (TTM)
25.97%
Net profit margin (TTM)
6.56%
Operating margin (TTM)
9.93%
Effective tax rate (TTM)
26.09%
Revenue per employee (TTM)
€130,000
Management effectiveness
Return on assets (TTM)
3.46%
Return on equity (TTM)
8.26%
Valuation
Price to earnings (TTM)
19.33
Price to revenue (TTM)
1.268
Price to book
1.46
Price to tangible book (TTM)
7.96
Price to free cash flow (TTM)
18.169
Free cash flow yield (TTM)
5.50%
Free cash flow per share (TTM)
2.926
Dividend yield (TTM)
1.98%
Forward dividend yield
1.98%
Growth
Revenue change (TTM)
3.73%
Earnings per share change (TTM)
35.52%
3-year revenue growth (CAGR)
3.39%
10-year revenue growth (CAGR)
-2.00%
3-year earnings per share growth (CAGR)
77.93%
10-year earnings per share growth (CAGR)
0.24%
3-year dividend per share growth (CAGR)
4.50%
10-year dividend per share growth (CAGR)
6.68%
What the Analysts think about Fresenius
Analyst ratings (Buy, Hold, Sell) for Fresenius stock.
Analyst projections of the future price of Fresenius stock.
Bulls say / Bears say
Third-quarter EBIT rose 10% and core EPS 14% at constant currency, and Fresenius lifted its full-year EPS outlook to the upper half of its 10–15% range. The stronger forecast points to improving earnings delivery, not just a one-quarter beat. (Fresenius)
Helios grew organic revenue by 5% and EBIT by 19% in constant currency in Q3, with growth in both Germany and Spain. The result supports the case that hospital activity and cost control can sustain earnings growth. (Fresenius)
Helios’ strong Q3 profit growth partly relied on a German reimbursement surcharge that expired at the end of October, as well as positive phasing effects. Those benefits make the quarter’s margin improvement harder to repeat. (Fresenius)
Fresenius said its TYENNE biosimilar lost preferred status on UnitedHealth’s Optum formulary. Although management said US demand remains strong, the change could make it harder to sustain growth for a key product. (Investing.com)
Kabi’s Nutrition business grew just 4% organically in Q3, with Fresenius citing temporary supply and procurement constraints in China. Continued disruption could limit growth in one of Kabi’s stated growth businesses. (Fresenius)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Fresenius Financial Performance
Revenues and expenses
Fresenius Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Fresenius
AllEURUSD
Fund name | Fund size | €FRE weighting |
|---|---|---|
iShares DivDAX€EXSB | €562M | 3.70% |
iShares Dax ESG€EXIA | €127M | 1.61% |
iShares MSCI Europe Health Care Sector£ESIH | €940M | 1.26% |
iShares MSCI Europe Health Care Sector€ESIH | €940M | 1.26% |
Xtrackers DAX£XDAX | €7.3B | 1.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.